Ингибиторыангиотензинпревращающего фермента влечении артериальной гипертензии и нетолько. Упрочение позиций
https://doi.org/10.18705/1607-419X-2010--5-
Аннотация
В данном обзоре представлены современные представления о роли ингибиторов ангиотензинпревращающего фермента в лечении пациентов с артериальной гипертензией, в том числе в замедлении прогрессирования сердечно-сосудистого континуума. Приведены основные результаты ключевых исследований с применением этого класса антигипертензивных препаратов, последние рекомендации по применению комбинированной терапии.
Об авторе
А. О. Конради
ФГУ «Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова Росмедтехнологий»
Россия
Россия
Список литературы
1. Fox K.M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Fox%20KM%22%5BAuthor%5D>. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators <http://www.ncbi.nlm.nih.gov/pubmed?term=%22EURopean%20trial%20On%20reduction%20of%20cardiac%20events%20with%20Perindopril%20in%20stable%20coronary%20Artery%20disease%20Investigators%22%5BCorporate%20Author%5D>. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) // Lancet. <javascript:AL_get(this,%20'jour',%20'Lancet.');> - 2003. - Vol. 362, № 9386. - P. 782-788
2.
3. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document // J. Hypertens. - 2009. - Vol. 27, № 11. - P. 2121-2158.
4.
5. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy // Lancet. - 2000. - Vol. 355, № 9200. - P. 253-259.
6.
7. PROGESS Collaborative Study Group. Randomised trial period of perindopril-based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischemic attack // Lancet. - 2001. - Vol. 358, № 9287. - P. 1033-1041.
8.
9. Hansson L., Lindholm L.H., Niskanen L. et al. Effects of angiotensin-converting enzyme inhibitor compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) // Lancet. - 1999. - Vol. 353, № 9153. - P. 611-616.
10.
11. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // J. Am. Med. Assoc. - 2002. - Vol. 288, № 23. - P. 2981-2997.
12.
13. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial // Lancet. - 2004. - Vol. 363, № 9426. - P. 2022-2031.
14.
15. Lindholm L.H., Ibsen T., Dahlöf B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in hypertension study (LIFE) // Lancet. - 2002. - Vol. 359, № 9311. - P. 1004-1010.
16.
17. Jong P <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Jong%20P%22%5BAuthor%5D>., Yusuf S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Yusuf%20S%22%5BAuthor%5D>., Rousseau M.F <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rousseau%20MF%22%5BAuthor%5D>., Ahn S.A <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ahn%20SA%22%5BAuthor%5D>., Bangdiwala S.I <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bangdiwala%20SI%22%5BAuthor%5D>. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study // Lancet. <javascript:AL_get(this,%20'jour',%20'Lancet.');> - 2003. - Vol. 361, № 9372. - P. 1843-1848.
18.
19. Sleight P <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sleight%20P%22%5BAuthor%5D>. Angiotensin II and trials of cardiovascular outcomes // Am. J. Cardiol. <javascript:AL_get(this,%20'jour',%20'Am%20J%20Cardiol.');> - 2002. - Vol. 89, № 2A. - P. 11A-16A.
20.
21. Healey J.S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Healey%20JS%22%5BAuthor%5D>., Baranchuk A <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Baranchuk%20A%22%5BAuthor%5D>., Crystal <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Crystal%20E%22%5BAuthor%5D> E. et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis // J. Am. Coll. Cardiol <javascript:AL_get(this,%20'jour',%20'J%20Am%20Coll%20Cardiol.');>. - 2005. - Vol. 45, № 11. - P. 1832-1839.
22.
23. Ruilope L.M., Alcazar J.M., Hernandez E., Praga M., Lahera V., Rodicio J.L. Long-term influence of antihypertensive therapy on microalbuminuria in essential hypertension // Kydney Int. - 1994. - Vol. 45. - P. S171-S173.
24.
25. Martinez M., Moreno A., Aguirre A. et al. Frequency and determinants of microalbuminuria in mild hypertension: a primary-care-based study // J. Hypertens. - 2001. - Vol. 19, № 2. - P. 319-326.
26.
27. Dahlöf B., Sever P.S., Poulter N.R. et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial // Lancet. - 2005. - Vol. 366, № 9489. - P. 895-906.
Рецензия
Для цитирования:
Конради А.О. Ингибиторыангиотензинпревращающего фермента влечении артериальной гипертензии и нетолько. Упрочение позиций. Артериальная гипертензия. 2010;16(5):464-468. https://doi.org/10.18705/1607-419X-2010--5-
For citation:
Konradi A.O. Angiotensin converting enzymeinhibitors in hypertension and beyond: The positionhardens. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2010;16(5):464-468. (In Russ.) https://doi.org/10.18705/1607-419X-2010--5-
Просмотров:
618
Послать статью по эл. почте 